Result of General Meeting

28 July 2025

Celadon Pharmaceuticals Plc

("Celadon" or the "Company")

Result of General Meeting

London, 28 July 2025: Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based pharmaceutical company focused on the research, cultivation, manufacturing, and sale of breakthrough cannabis-based medicines, announces that at the general meeting of the Company held earlier today (the "General Meeting"), all resolutions put to the Company's shareholders ("Shareholders") were duly passed.

Full details of the poll results are set out below.

The full text of the Resolutions proposed and passed at the General Meeting can be found in the Circular containing, inter alia, the Notice of General Meeting, which was published on 2 July 2025 and is available on the Company's website www.celadonpharma.com.

AIM Cancellation

Following approval by Shareholders at the General Meeting, the admission of the Ordinary Shares to trading on AIM will be cancelled. The Cancellation is expected to take place at 7:00 a.m. on 8 August 2025 and, accordingly, the last day of dealings in Ordinary Shares on AIM is expected to be 7 August 2025.

The Ordinary Shares are currently suspended from trading on AIM as the Company has not been able to publish its report & accounts for the year ended 31 December 2024 by 30 June 2025. It is not expected that the Company will be able to publish its report & accounts for the year ended 31 December 2024 by 7 August 2025 and as such the suspension from trading on AIM is not expected to be lifted prior to Cancellation.

Re-registration as a private company

In accordance with the passing of Resolution 3, the Company will re-register as a private limited company and adopt new articles of association, which is expected to take place by 15 August 2025.

Matched Bargain Facility

The Company has made arrangements for the Matched Bargain Facility to assist Shareholders to trade in the Ordinary Shares from the date of Cancellation, if the Cancellation Resolution is passed. The Matched Bargain Facility will be provided by J P Jenkins, which is an appointed representative of Prosper Capital LLP, which is authorised and regulated by the UK Financial Conduct Authority. Under the Matched Bargain Facility, Shareholders or persons wishing to acquire or dispose of Ordinary Shares will be able to leave an indication with J P Jenkins, through their stockbroker, of the number of Ordinary Shares that they are prepared to buy or sell and the price at which they are prepared to do so. In the event that J P Jenkins is able to match that order with an opposite sell or buy instruction, it would contact both parties and then effect the bargain (trade). Should the Cancellation become effective, the Matched Bargain Facility will commence, and details will be made available to Shareholders on the Company's website. It should be noted, however, that there is no guarantee as to the liquidity such a facility would afford the Ordinary Shares post Cancellation.

Capitalised terms used but not defined in this announcement shall have the same meaning given to such terms in the Circular and the announcement dated 2 July 2025.

Enquiries:

About Celadon Pharmaceuticals Plc

Celadon Pharmaceuticals Plc is a UK-based pharmaceutical company focused on the development, production and sale of breakthrough cannabis-based medicines. Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabis-based medicines for other conditions such as autism. Its 100,000 sq. ft UK facility is EU-GMP approved and comprises indoor hydroponic cultivation, proprietary GMP extraction and an analytical and R&D laboratory. Celadon's Home Office licence allows for the commercial supply of its pharmaceutical-grade cannabis product. The Group owns an approved clinical trial using cannabis-based medicinal products to treat chronic pain in the UK. Celadon also has a minority interest in early-stage biopharma Kingdom Therapeutics, which is developing a licensed cannabinoid medicine to treat children with Autism Spectrum Disorder.

For further information please visit our website www.celadonpharma.com

This announcement contains inside information for the purposes of article 7 of the Market Abuse Regulation (EU) 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310. With the publication of this announcement, this information is now considered to be in the public domain.